LAVA Therapeutics N.V. Financials
This page shows LAVA Therapeutics N.V. (LVTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
LAVA Therapeutics N.V. has an operating margin of -247.8%, meaning the company retains $-248 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -641.1% the prior year.
LAVA Therapeutics N.V.'s revenue surged 77.0% year-over-year to $12.0M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
LAVA Therapeutics N.V. carries a low D/E ratio of 0.18, meaning only $0.18 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.40, LAVA Therapeutics N.V. holds $4.40 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 87/100.
While LAVA Therapeutics N.V. generated -$19.5M in operating cash flow, capex of $23K consumed most of it, leaving -$19.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
LAVA Therapeutics N.V. generates a -90.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -81.5% the prior year.
LAVA Therapeutics N.V. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, LAVA Therapeutics N.V. generates $0.78 in operating cash flow (-$19.5M OCF vs -$25.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
LAVA Therapeutics N.V. earns $-59.4 in operating income for every $1 of interest expense (-$29.7M vs $500K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
LAVA Therapeutics N.V. generated $12.0M in revenue in fiscal year 2024. This represents an increase of 77.0% from the prior year.
LAVA Therapeutics N.V.'s EBITDA was -$29.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 31.7% from the prior year.
LAVA Therapeutics N.V. reported -$25.1M in net income in fiscal year 2024. This represents an increase of 40.0% from the prior year.
LAVA Therapeutics N.V. earned $-0.94 per diluted share (EPS) in fiscal year 2024. This represents an increase of 40.1% from the prior year.
Cash & Balance Sheet
LAVA Therapeutics N.V. generated -$19.6M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 52.3% from the prior year.
LAVA Therapeutics N.V. held $35.0M in cash against $4.9M in long-term debt as of fiscal year 2024.
LAVA Therapeutics N.V. had 26M shares outstanding in fiscal year 2024. This represents an increase of 0.1% from the prior year.
Margins & Returns
LAVA Therapeutics N.V.'s operating margin was -247.8% in fiscal year 2024, reflecting core business profitability. This is up 393.3 percentage points from the prior year.
LAVA Therapeutics N.V.'s net profit margin was -209.6% in fiscal year 2024, showing the share of revenue converted to profit. This is up 409.0 percentage points from the prior year.
LAVA Therapeutics N.V.'s ROE was -90.5% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 9.0 percentage points from the prior year.
Capital Allocation
LAVA Therapeutics N.V. invested $28.4M in research and development in fiscal year 2024. This represents a decrease of 12.6% from the prior year.
LAVA Therapeutics N.V. invested $23K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 96.9% from the prior year.
LVTX Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | $7.0M | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.2M-52.8% | $4.7M+14.0% | $4.2M | N/A | $8.3M+38.9% | $6.0M+5.5% | $5.6M | N/A |
| SG&A Expenses | $5.3M+108.4% | $2.5M-25.7% | $3.4M | N/A | $3.1M-10.8% | $3.4M+1.6% | $3.4M | N/A |
| Operating Income | -$7.6M-3.6% | -$7.3M+3.9% | -$7.6M | N/A | -$11.3M-20.7% | -$9.4M-361.3% | -$2.0M | N/A |
| Interest Expense | N/A | $0-100.0% | $100K | N/A | $100K0.0% | $100K-23.1% | $130K | N/A |
| Income Tax | $6K-91.7% | $72K-68.0% | $225K | N/A | $96K+11.6% | $86K+24.6% | $69K | N/A |
| Net Income | -$7.2M+16.8% | -$8.6M-148.3% | -$3.5M | N/A | -$12.3M-48.5% | -$8.3M-1265.1% | -$608K | N/A |
| EPS (Diluted) | $-0.27+15.6% | $-0.32-146.2% | $-0.13 | N/A | $-0.46-48.4% | $-0.31-1450.0% | $-0.02 | N/A |
LVTX Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $51.9M-14.3% | $60.5M-14.9% | $71.2M-12.0% | $80.8M | N/A | N/A | N/A | $101.7M |
| Current Assets | $51.9M-14.2% | $60.5M-13.3% | $69.8M-12.0% | $79.3M | N/A | N/A | N/A | $98.9M |
| Cash & Equivalents | $49.7M+88.3% | $26.4M-33.5% | $39.7M+13.3% | $35.0M+29.8% | $27.0M-23.1% | $35.1M-18.8% | $43.2M-2.4% | $44.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $39.2M-3.4% | $40.6M-10.5% | $45.4M-14.5% | $53.1M | N/A | N/A | N/A | $50.3M |
| Current Liabilities | $4.2M-24.6% | $5.6M-45.9% | $10.4M-42.4% | $18.0M | N/A | N/A | N/A | $14.9M |
| Long-Term Debt | N/A | N/A | N/A | $4.9M | N/A | N/A | N/A | $5.3M |
| Total Equity | $12.7M-36.4% | $19.9M-22.7% | $25.8M-7.1% | $27.7M-16.0% | $33.0M-23.0% | $42.9M-15.5% | $50.8M-1.1% | $51.4M |
| Retained Earnings | -$194.3M-3.8% | -$187.1M-4.8% | -$178.5M-2.0% | -$175.0M | N/A | N/A | N/A | -$149.9M |
LVTX Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.9M+64.6% | -$13.7M-18.1% | -$11.6M-2257.3% | -$494K+95.1% | -$10.0M-21.7% | -$8.2M-874.4% | -$843K | N/A |
| Capital Expenditures | N/A | N/A | N/A | $0 | N/A | N/A | $23K | N/A |
| Free Cash Flow | N/A | N/A | N/A | -$494K | N/A | N/A | -$866K | N/A |
| Investing Cash Flow | $27.7M+1209.4% | -$2.5M-116.5% | $15.2M+38.1% | $11.0M+2383.3% | $442K+21.8% | $363K-47.7% | $694K | N/A |
| Financing Cash Flow | N/A | N/A | N/A | -$594K-59500.0% | $1K-93.8% | $16K+100.0% | $8K | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
LVTX Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | -29.1% | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | -8.7% | N/A |
| Return on Equity | -56.7%-13.3pp | -43.3%-29.8pp | -13.5% | N/A | -37.3%-18.0pp | -19.3%-18.1pp | -1.2% | N/A |
| Return on Assets | -13.9%+0.4pp | -14.3%-9.4pp | -4.9% | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | 12.27+1.5 | 10.78+4.0 | 6.73+2.3 | 4.40 | N/A | N/A | N/A | 6.64 |
| Debt-to-Equity | 3.09+1.1 | 2.04+0.3 | 1.76+1.6 | 0.18 | N/A | N/A | N/A | 0.10 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | -12.4% | N/A |
Similar Companies
Frequently Asked Questions
What is LAVA Therapeutics N.V.'s annual revenue?
LAVA Therapeutics N.V. (LVTX) reported $12.0M in total revenue for fiscal year 2024. This represents a 77.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is LAVA Therapeutics N.V.'s revenue growing?
LAVA Therapeutics N.V. (LVTX) revenue grew by 77% year-over-year, from $6.8M to $12.0M in fiscal year 2024.
Is LAVA Therapeutics N.V. profitable?
No, LAVA Therapeutics N.V. (LVTX) reported a net income of -$25.1M in fiscal year 2024, with a net profit margin of -209.6%.
What is LAVA Therapeutics N.V.'s EBITDA?
LAVA Therapeutics N.V. (LVTX) had EBITDA of -$29.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does LAVA Therapeutics N.V. have?
As of fiscal year 2024, LAVA Therapeutics N.V. (LVTX) had $35.0M in cash and equivalents against $4.9M in long-term debt.
What is LAVA Therapeutics N.V.'s operating margin?
LAVA Therapeutics N.V. (LVTX) had an operating margin of -247.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is LAVA Therapeutics N.V.'s net profit margin?
LAVA Therapeutics N.V. (LVTX) had a net profit margin of -209.6% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is LAVA Therapeutics N.V.'s return on equity (ROE)?
LAVA Therapeutics N.V. (LVTX) has a return on equity of -90.5% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is LAVA Therapeutics N.V.'s free cash flow?
LAVA Therapeutics N.V. (LVTX) generated -$19.6M in free cash flow during fiscal year 2024. This represents a 52.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is LAVA Therapeutics N.V.'s operating cash flow?
LAVA Therapeutics N.V. (LVTX) generated -$19.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are LAVA Therapeutics N.V.'s total assets?
LAVA Therapeutics N.V. (LVTX) had $80.8M in total assets as of fiscal year 2024, including both current and long-term assets.
What are LAVA Therapeutics N.V.'s capital expenditures?
LAVA Therapeutics N.V. (LVTX) invested $23K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does LAVA Therapeutics N.V. spend on research and development?
LAVA Therapeutics N.V. (LVTX) invested $28.4M in research and development during fiscal year 2024.
What is LAVA Therapeutics N.V.'s current ratio?
LAVA Therapeutics N.V. (LVTX) had a current ratio of 4.40 as of fiscal year 2024, which is generally considered healthy.
What is LAVA Therapeutics N.V.'s debt-to-equity ratio?
LAVA Therapeutics N.V. (LVTX) had a debt-to-equity ratio of 0.18 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is LAVA Therapeutics N.V.'s return on assets (ROA)?
LAVA Therapeutics N.V. (LVTX) had a return on assets of -31.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is LAVA Therapeutics N.V.'s cash runway?
Based on fiscal year 2024 data, LAVA Therapeutics N.V. (LVTX) had $35.0M in cash against an annual operating cash burn of $19.5M. This gives an estimated cash runway of approximately 21 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is LAVA Therapeutics N.V.'s Piotroski F-Score?
LAVA Therapeutics N.V. (LVTX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are LAVA Therapeutics N.V.'s earnings high quality?
LAVA Therapeutics N.V. (LVTX) has an earnings quality ratio of 0.78x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can LAVA Therapeutics N.V. cover its interest payments?
LAVA Therapeutics N.V. (LVTX) has an interest coverage ratio of -59.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is LAVA Therapeutics N.V.?
LAVA Therapeutics N.V. (LVTX) scores 48 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.